Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
crispr
3
×
detroit blog main
detroit top stories
fda
3
×
gene editing
glaxosmithkline
life sciences
national
national blog main
3
×
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
3
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
3
×
wisconsin top stories
biotech
celgene
clinical study
commissioner
congress
democrats
eli lilly
failure
gene therapy
indiana blog main
indiana top stories
ipo
What
bio
crispr
3
×
roundup
new
allogene
big
biopharma
bosley's
bosley’s
bridge
bucks
cancer
cas
ceo
congress
congressional
crime
departure
diversity
editas
executives
exit
feud
group
guiding
hot
immunotherapy
investors
ipo
isn’t
juno
katrine
known
later
medicine
million
month
moves
nearly
ny
Language
Current search:
crispr
×
crispr
×
" national blog main "
×
" wisconsin blog main "
×
fda
×
" seattle blog main "
×
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More